(ANRO) Alto Neuroscience - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NYSE (USA) | Market Cap: 729m USD | Total Return: 624.2% in 12m
Avg Turnover: 6.39M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Share dilution 21.6% YoY
Interest Coverage Ratio -30.4 is critical
Altman Z'' -6.08 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader
Alto Neuroscience, Inc. (ANRO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for psychiatric conditions. The company utilizes a biomarker-driven approach to match patients with specific therapies based on neurobiology, a model designed to improve the historically low success rates of central nervous system (CNS) drug development.
The current pipeline features several mid-stage candidates, including ALTO-100 and ALTO-300, which are undergoing Phase 2b trials for bipolar depression and major depressive disorder, respectively. Additional programs target cognitive impairment in schizophrenia and anhedonia through novel small-molecule mechanisms such as phosphodiesterase 4 inhibition and H3 receptor antagonism. Clinical-stage biotech firms often face significant capital requirements and regulatory hurdles before achieving commercialization.
Investors looking for deeper fundamental metrics and valuation models might find ValueRay a useful resource for further due diligence. The company is headquartered in Mountain View, California, and has been operational since 2019.
- Phase 2b clinical trial results for ALTO-100 determine near-term valuation
- Precision psychiatry platform efficacy drives investor confidence in patient stratification
- Research and development expenses accelerate as multiple assets enter mid-stage trials
- FDA regulatory pathways for biomarker-defined treatments influence long-term commercial viability
- Cash runway and future equity financing needs impact share price stability
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA 9.57 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -62.3m > Net Income -74.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 20.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.9m) vs 12m ago 21.61% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.23%; Δ -0.23% > 0%) |
| Interest Coverage Ratio: -30.35 > 6 (EBITDA TTM -72.7m / Interest Expense TTM 2.42m) |
| A: 0.93 (Total Current Assets 269.1m - Total Current Liabilities 13.1m) / Total Assets 276.3m |
| B: -0.82 (Retained Earnings -227.9m / Total Assets 276.3m) |
| C: -0.33 (EBIT TTM -73.3m / Avg Total Assets 224.1m) |
| D: -6.93 (Book Value of Equity -227.9m / Total Liabilities 32.9m) |
| Altman-Z'' = -6.08 = D |
As of May 24, 2026, the stock is trading at USD 21.22 with a total of 269,937 shares traded.
Over the past week, the price has changed by -7.66%,
over one month by -21.87%,
over three months by +15.96% and
over the past year by +624.23%.
Alto Neuroscience has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ANRO.
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.3 | 66.5% |
Revenue TTM = 0.0 USD
EBIT TTM = -73.3m USD
EBITDA TTM = -72.7m USD
Long Term Debt = 16.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.14m USD (from shortTermDebt, last quarter)
Debt = 23.2m USD (corrected: LT Debt 16.2m + ST Debt 2.14m) + Leases 4.86m
Net Debt = -225.8m USD (calculated: Debt 23.2m - CCE 249.1m)
Enterprise Value = 503.4m USD (729.3m + Debt 23.2m - CCE 249.1m)
Interest Coverage Ratio = -30.35 (Ebit TTM -73.3m / Interest Expense TTM 2.42m)
EV/FCF = -7.72x (Enterprise Value 503.4m / FCF TTM -65.2m)
FCF Yield = -12.96% (FCF TTM -65.2m / Enterprise Value 503.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 605k) / Revenue TTM)
Tobins Q-Ratio = 1.82 (Enterprise Value 503.4m / Total Assets 276.3m)
Interest Expense / Debt = 10.41% (Interest Expense 2.42m / Debt 23.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -57.9m (EBIT -73.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.33 (Total Current Assets 269.1m / Total Current Liabilities 16.5m)
Debt / Equity = 0.10 (Debt 23.2m / totalStockholderEquity, last quarter 243.4m)
Debt / EBITDA = 3.11 (negative EBITDA) (Net Debt -225.8m / EBITDA -72.7m)
Debt / FCF = 3.46 (negative FCF - burning cash) (Net Debt -225.8m / FCF TTM -65.2m)
Total Stockholder Equity = 157.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.16% (Net Income -74.3m / Total Assets 276.3m)
RoE = -19.29% (Net Income TTM -74.3m / Total Stockholder Equity 385.2m)
RoCE = -18.27% (EBIT -73.3m / Capital Employed (Equity 385.2m + L.T.Debt 16.2m))
RoIC = -21.84% (negative operating profit) (NOPAT -57.9m / Invested Capital 265.3m)
WACC = 9.59% (E(729.3m)/V(752.5m) * Re(9.63%) + D(23.2m)/V(752.5m) * Rd(10.41%) * (1-Tc(0.21)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 9.38%
[DCF] Fair Price = unknown (Cash Flow -65.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.96 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.71 | Chg30d=-41.50% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.76 | Chg30d=-37.73% | Revisions=-20% | Analysts=4
EPS current Year (2026-12-31): EPS=-3.10 | Chg30d=-47.46% | Revisions=-20% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.94 | Chg30d=-29.12% | Revisions=-33% | GrowthEPS=+5.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -33%